C. Light Technologies

C. Light Technologies operates at the intersection of medical devices, neurotechnology, digital diagnostics, and clinical software. Its differentiation is a retinal eye-tracking approach that measures fixational eye movements that may not be visible in standard bedside examinations, rather than relying only on conventional visual-acuity or neurological assessments. Retitrack™ is positioned for objective monitoring across neurodegenerative disease, concussion, acquired brain injury, and sports vision, giving the company a broader potential application set than a single-disease diagnostic. The platform also combines non-invasive retinal imaging with artificial intelligence, machine learning, and data analytics. The company’s 2021 seed financing of $4.1 million, participation in the 2025 Roche MS Innovation Challenge, and six granted patents indicate activity across capital formation, clinical validation, and intellectual property. Its market position therefore appears to be that of a specialized early-stage medical-device and software developer, with differentiation centered on high-resolution retinal movement data rather than a demonstrated large commercial footprint.

C. Light Technologies has followed a research-led financing path since its September 2014 founding. It raised $740,000 in a 2017 pre-seed round, followed by an undisclosed 2018 pre-seed round and $100,000 in February 2020. The company then reached a significant financing inflection point with a $4.1 million seed round on Feb 2, 2021, backed by Creative Ventures and a broad group of investors including Yamaha Motor Ventures, Berkeley SkyDeck Fund, Band of Angels, and EGB Capital. A further $251,021 venture round from the Alzheimer’s Drug Discovery Foundation closed on Aug 4, 2021. The latest recorded financing was a DayOne accelerator grant on Aug 21, 2025, with no amount disclosed. Product-wise, Retitrack™ provides a 10-second retinal eye scan intended to monitor neurodegenerative disease, while patent activity in 2021, 2022, and 2023 supports continued technical development. Selection in the Roche MS Innovation Challenge on Nov 19, 2025 is a newer validation milestone and may broaden clinical relevance toward multiple sclerosis. Growth remains difficult to quantify because hiring data, revenue, customer counts, and employee-growth trends are unavailable.